Delivering affordable cancer care in high-income countries
- PMID: 21958503
- DOI: 10.1016/S1470-2045(11)70141-3
Delivering affordable cancer care in high-income countries
Abstract
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Comment in
-
Striking a balance between idealism and fatalism.Lancet Oncol. 2011 Sep;12(10):923-4. doi: 10.1016/S1470-2045(11)70225-X. Lancet Oncol. 2011. PMID: 21958496 No abstract available.
-
…And the only side-effects are good ones.Lancet Oncol. 2011 Sep;12(10):924-5. doi: 10.1016/S1470-2045(11)70227-3. Lancet Oncol. 2011. PMID: 21958497 No abstract available.
-
Challenges related to palliative care.Lancet Oncol. 2011 Sep;12(10):925-7. doi: 10.1016/S1470-2045(11)70226-1. Lancet Oncol. 2011. PMID: 21958498 No abstract available.
-
Paediatric oncology: are there ways to bend the costs?Lancet Oncol. 2011 Sep;12(10):927-8. doi: 10.1016/S1470-2045(11)70224-8. Lancet Oncol. 2011. PMID: 21958499 No abstract available.
-
Caring for patients with haematological malignancies.Lancet Oncol. 2011 Sep;12(10):928-9. doi: 10.1016/S1470-2045(11)70217-0. Lancet Oncol. 2011. PMID: 21958500 No abstract available.
-
Regulators, payers, and prescribers: can we fill the gaps?Lancet Oncol. 2011 Sep;12(10):930-1. doi: 10.1016/S1470-2045(11)70229-7. Lancet Oncol. 2011. PMID: 21958501 No abstract available.
-
The opportunity cost of cancer care: a statement from NICE.Lancet Oncol. 2011 Sep;12(10):931-2. doi: 10.1016/S1470-2045(11)70218-2. Lancet Oncol. 2011. PMID: 21958502 No abstract available.
-
Analysis of media reporting of The Lancet Oncology Commission.Lancet Oncol. 2012 Jan;13(1):12-3. doi: 10.1016/S1470-2045(11)70380-1. Lancet Oncol. 2012. PMID: 22225716 No abstract available.
-
Drivers of the cost of cancer care.Lancet Oncol. 2012 Jan;13(1):14-5. doi: 10.1016/S1470-2045(11)70370-9. Lancet Oncol. 2012. PMID: 22225717 No abstract available.
-
Cancer care after the National Health Service reforms.Lancet Oncol. 2012 Jan;13(1):15-6. doi: 10.1016/S1470-2045(11)70371-0. Lancet Oncol. 2012. PMID: 22225718 No abstract available.
-
Affordable cancer care.Lancet Oncol. 2012 Jan;13(1):e2-3. doi: 10.1016/S1470-2045(11)70419-3. Lancet Oncol. 2012. PMID: 22225720 No abstract available.
-
What price cure?Lancet Oncol. 2012 Jan;13(1):e2. doi: 10.1016/S1470-2045(11)70418-1. Lancet Oncol. 2012. PMID: 22225721 No abstract available.
-
Re: delivering affordable cancer care in high-income countries.J Urol. 2012 May;187(5):1795. doi: 10.1016/j.juro.2012.01.093. Epub 2012 Mar 21. J Urol. 2012. PMID: 22494754 No abstract available.
Similar articles
-
American Society of Clinical Oncology guidance statement: the cost of cancer care.J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6. J Clin Oncol. 2009. PMID: 19581533
-
Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.Oncology (Williston Park). 2013 Sep;27(9):865-6, 871. Oncology (Williston Park). 2013. PMID: 24282981 No abstract available.
-
How the Affordable Care Act Has Affected Cancer Care in the United States: Has Value for Cancer Patients Improved?Oncology (Williston Park). 2016 May;30(5):468-74. Oncology (Williston Park). 2016. PMID: 27188679 Review. No abstract available.
-
From Obamacare to markets in artificial organs.Artif Organs. 2013 Mar;37(3):229-32. doi: 10.1111/aor.12055. Artif Organs. 2013. PMID: 23458329 No abstract available.
-
Pricing-out effect from possible user-fee policies under Taiwan's National Health Insurance.Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):453-64. doi: 10.1586/erp.10.43. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20715921 Review.
Cited by
-
The need for economic evaluation in primary prevention of cancer.Can J Public Health. 2012 Nov 6;103(5):e395-6. doi: 10.1007/BF03404449. Can J Public Health. 2012. PMID: 23617996 Free PMC article. No abstract available.
-
First do no harm: the review frequency of illness depends as much on family dynamics as on material factors.Br J Gen Pract. 2013 Feb;63(607):94. doi: 10.3399/bjgp13X663145. Br J Gen Pract. 2013. PMID: 23561678 Free PMC article. No abstract available.
-
Neuroimmune Regulation of Surgery-Associated Metastases.Cells. 2021 Feb 20;10(2):454. doi: 10.3390/cells10020454. Cells. 2021. PMID: 33672617 Free PMC article. Review.
-
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary.J Manag Care Spec Pharm. 2020 Jul;26(7):826-831. doi: 10.18553/jmcp.2020.26.7.826. J Manag Care Spec Pharm. 2020. PMID: 32584682 Free PMC article. Review.
-
Health care costs: how do we decide value? When do we decide? How do we particularize the decisions?Oncologist. 2012;17(2):157-9. doi: 10.1634/theoncologist.2011-0371. Epub 2012 Feb 2. Oncologist. 2012. PMID: 22302226 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources